20 March 2015Americas

BMS sues Mylan to block Reyataz generic

Bristol-Myers Squibb (BMS) has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz (atazanavir sulphate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
12 September 2017   Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).

More on this story

Americas
12 September 2017   Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).

More on this story

Americas
12 September 2017   Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).